GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Short Interest

Ryvu Therapeutics (FRA:9Y4) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ryvu Therapeutics's Short Interest

For the Biotechnology subindustry, Ryvu Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Short Interest falls into.


;
;

Ryvu Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Short Interest
Comparable Companies
WAR:BCX WAR:SVE WAR:BIO WAR:CTX WAR:MOC WAR:PTG WAR:MAB WAR:URT WAR:NNG WAR:PHR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
RVU:Poland
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Website
https://www.ryvu.com
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines